JP2020514345A - 新規な癌の治療法 - Google Patents
新規な癌の治療法 Download PDFInfo
- Publication number
- JP2020514345A JP2020514345A JP2019549449A JP2019549449A JP2020514345A JP 2020514345 A JP2020514345 A JP 2020514345A JP 2019549449 A JP2019549449 A JP 2019549449A JP 2019549449 A JP2019549449 A JP 2019549449A JP 2020514345 A JP2020514345 A JP 2020514345A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pyridin
- sdf
- fpkm
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703907.4A GB201703907D0 (en) | 2017-03-10 | 2017-03-10 | Novel therapies for cancer |
| GB1703907.4 | 2017-03-10 | ||
| PCT/GB2018/050608 WO2018162924A1 (en) | 2017-03-10 | 2018-03-09 | Usl-311 for use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514345A true JP2020514345A (ja) | 2020-05-21 |
| JP2020514345A5 JP2020514345A5 (enExample) | 2021-04-22 |
Family
ID=58605592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549449A Pending JP2020514345A (ja) | 2017-03-10 | 2018-03-09 | 新規な癌の治療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200281937A1 (enExample) |
| EP (1) | EP3592356A1 (enExample) |
| JP (1) | JP2020514345A (enExample) |
| KR (1) | KR20190128660A (enExample) |
| CN (1) | CN110520130A (enExample) |
| AU (1) | AU2018231664A1 (enExample) |
| BR (1) | BR112019018482A2 (enExample) |
| CA (1) | CA3055470A1 (enExample) |
| EA (1) | EA201992130A1 (enExample) |
| GB (1) | GB201703907D0 (enExample) |
| IL (1) | IL269121A (enExample) |
| MX (1) | MX2019010679A (enExample) |
| SG (1) | SG11201908166UA (enExample) |
| WO (1) | WO2018162924A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| PL3277284T3 (pl) | 2015-04-02 | 2021-03-08 | Proximagen, Llc | Nowe terapie nowotworu |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013539777A (ja) * | 2010-10-14 | 2013-10-28 | プロクシマゲン リミテッド | Ｃｘｃｒ４受容体アンタゴニスト |
| JP2016527303A (ja) * | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害 |
| WO2016157149A1 (en) * | 2015-04-02 | 2016-10-06 | Proximagen Limited | Novel therapies for cancer |
| JP2019513150A (ja) * | 2016-03-11 | 2019-05-23 | プロキシマジェン, エルエルシーProximagen, Llc | Ｃｘｃｒ４アンタゴニストと免疫チェックポイント阻害剤との組合せ |
-
2017
- 2017-03-10 GB GBGB1703907.4A patent/GB201703907D0/en not_active Ceased
-
2018
- 2018-03-09 AU AU2018231664A patent/AU2018231664A1/en not_active Abandoned
- 2018-03-09 MX MX2019010679A patent/MX2019010679A/es unknown
- 2018-03-09 US US16/492,305 patent/US20200281937A1/en not_active Abandoned
- 2018-03-09 CN CN201880024349.5A patent/CN110520130A/zh active Pending
- 2018-03-09 KR KR1020197028679A patent/KR20190128660A/ko not_active Ceased
- 2018-03-09 EA EA201992130A patent/EA201992130A1/ru unknown
- 2018-03-09 BR BR112019018482A patent/BR112019018482A2/pt not_active Application Discontinuation
- 2018-03-09 CA CA3055470A patent/CA3055470A1/en not_active Abandoned
- 2018-03-09 SG SG11201908166U patent/SG11201908166UA/en unknown
- 2018-03-09 JP JP2019549449A patent/JP2020514345A/ja active Pending
- 2018-03-09 WO PCT/GB2018/050608 patent/WO2018162924A1/en not_active Ceased
- 2018-03-09 EP EP18711658.7A patent/EP3592356A1/en not_active Withdrawn
-
2019
- 2019-09-04 IL IL26912119A patent/IL269121A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013539777A (ja) * | 2010-10-14 | 2013-10-28 | プロクシマゲン リミテッド | Ｃｘｃｒ４受容体アンタゴニスト |
| JP2016527303A (ja) * | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害 |
| WO2016157149A1 (en) * | 2015-04-02 | 2016-10-06 | Proximagen Limited | Novel therapies for cancer |
| JP2019513150A (ja) * | 2016-03-11 | 2019-05-23 | プロキシマジェン, エルエルシーProximagen, Llc | Ｃｘｃｒ４アンタゴニストと免疫チェックポイント阻害剤との組合せ |
Non-Patent Citations (1)
| Title |
|---|
| J. ENDOCRINOL. INVEST., vol. 31, JPN6022001045, 2008, pages 809 - 819, ISSN: 0004845446 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201908166UA (en) | 2019-10-30 |
| AU2018231664A1 (en) | 2019-09-26 |
| EA201992130A1 (ru) | 2020-02-04 |
| CA3055470A1 (en) | 2018-09-13 |
| BR112019018482A2 (pt) | 2020-04-14 |
| EP3592356A1 (en) | 2020-01-15 |
| CN110520130A (zh) | 2019-11-29 |
| US20200281937A1 (en) | 2020-09-10 |
| GB201703907D0 (en) | 2017-04-26 |
| KR20190128660A (ko) | 2019-11-18 |
| MX2019010679A (es) | 2020-02-05 |
| IL269121A (en) | 2019-11-28 |
| WO2018162924A1 (en) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111971279B (zh) | 趋化因子受体调节剂及其用途 | |
| US11369616B2 (en) | Drug combination and its use in therapy | |
| EP3843850B1 (en) | Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| JP6192708B2 (ja) | Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 | |
| WO2020027083A1 (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| JP2021531314A (ja) | ピリドンａ２ｒアンタゴニスト | |
| JP2021501779A (ja) | 統合的ストレス経路の調節剤 | |
| KR20180052623A (ko) | 신규 화합물 | |
| US20250199015A1 (en) | Cyclin-dependent kinase 2 inhibitors for medical treatment | |
| TW202508564A (zh) | Ｋｒａｓ調節化合物 | |
| JP2020514345A (ja) | 新規な癌の治療法 | |
| JP2019069990A (ja) | 癌を処置するためのセファロスポリンの新規誘導体 | |
| CN104024243A (zh) | 作为酪氨酸激酶抑制剂的新咪唑并吡啶衍生物 | |
| CN119585256A (zh) | 趋化因子受体调节剂及其用途 | |
| TWI745824B (zh) | 作為tam及met激酶抑制劑之喹啉化合物 | |
| KR20180052631A (ko) | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 | |
| JP6945587B2 (ja) | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 | |
| TW202504894A (zh) | Ｐａｒｐ７抑制劑 | |
| HK40053753A (en) | Quinoline compounds as inhibitors of tam and met kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220809 |